SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences gets USFDA’s final approval for Doxepin Hydrochloride Capsules

28 Mar 2023 Evaluate

Zydus Lifesciences has received final approval for Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg (USRLD: Sinequan Capsules) from the United States Food and Drug Administration (USFDA).Doxepin Hydrochloride capsule is recommended for the treatment of Psychoneurotic patients with depression and/or anxiety, Depression and/or anxiety associated with alcoholism and organic disease, and Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).

Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg had annual sales of $28.9 million in the United States (IQVIA MAT Jan. 2023). The group now has 355 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.

Recently, the company had received final approval for Doxepin Hydrochloride Capsules USP, 150 mg (USRLD: Sinequan Capsules) from the United States Food and Drug Administration.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Zydus Lifesciences Share Price

943.05 0.50 (0.05%)
20-Apr-2026 12:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.45
Dr. Reddys Lab 1237.15
Cipla 1237.30
Zydus Lifesciences 943.05
Lupin 2332.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×